Branded Generics Market: Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Global Branded Generics Market By Disease Indication (Cardiovascular Diseases, Diabetes, Cancer, Neurological Disorders, Gastrointestinal Diseases, Dermatology Diseases, and Others), By Route of Administration (Oral, Parenteral, Topical, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global branded generics market size valued US$ 224.0 billion in 2017 and expected to reach US$ 350.0 billion by 2023, poised to grow at CAGR 7.7 % during forecast period 2021-2023. Branded generics are the most recent version of an off-patent drug that is promoted by either a patented drug manufacturer or generic drug companies that build brand equity for their generic drug versions. The pharmaceutical sector is characterised by a number of internal and external dynamics linked to licencing, production, and marketing. The notion of patenting is extremely important in the pharmaceutical industry. The branded generics market expected to register around double-digit growth rate in emerging economies owing to the widespread prevalence of lifestyle and chronic diseases like diabetes and cardiovascular diseases. The growing lifestyle changes along with rising disposable income in middle classes are factors expected to prompt the market growth in near future. According to International Diabetes Federation (IDF) atlas, 2015 emerging nations like India and China, Brazil and Russia fall under top ten countries for diabetic population. This report studies branded generics market dynamics in emerging markets and developed markets elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes new product introductions, recent drug patent expiration data, regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the competition. Moreover, PBI analyzed branded generics market to better equip clients with possible investment opportunities across the emerging markets (Regional Investment Hot-Spots) and unmet needs (Product/Disease Opportunities).

Branded Generics Market

MARKET SUMMARY
-
7.7 % CAGR
  • Study Period– 2021 – 2023
  • Base Year– 2020
  • CAGR– 7.7 %
  • Largest Market– Asia-Pacific
  • Fastest Growing Market– Europe

Branded Generics Market

  • The report on global branded generics market gives historical, current and future market sizes (US$ Bn) based on by disease indication, by route of administration, by distribution channel and geographical regions.
  • branded generics market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • Key stakeholders of the branded generics market report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of branded generics.
Key Players
  • Abbott Laboratories (U.S.)
  • Apotex Inc. (Canada)
  • AstraZeneca (U.K)
  • GlaxoSmithKline plc (U.K)
  • Mylan N.V. (U.S.)
  • Pfizer Inc. (U.S)
Branded Generics Market

Drivers And Restraints

Developed pharmaceutical markets like North America, Europe, and Japan has been witnessing relatively slower market growth in comparing with developing markets owing to fewer new product approvals from the regulatory bodies and bleak late-stage pipeline. This has been led to the change in focus by several multinational pharmaceutical giants from matured markets to developing markets to tap ever-growing market opportunities in these regions. Moreover, increasing product patent expirations expected to boost the branded generics revenue growth in developing and mature markets across the globe.


North-America got significant share

Branded Generics Market

Asia-pacific expected to lead the global Branded Generics Market in terms of revenue in over forecast period owing to higher out-of-pocket healthcare expenditure and lack of universal health coverage. Moreover, countries like India, China, and ASEAN countries presented better growth opportunities for the existing and new players in the market. Regions such as Asia Latin America and Eastern Europe projected to grow at significant CAGR over the forecast period

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015-2020) and forecast (2021-2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Key

Key Findings of the Report

Branded Generics Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content

1. Research Methodology

      1.1. Secondary and Primary research
            1.1.1. Secondary Sources
            1.1.2. Primary Sources
      1.2. Market Revenue Estimation Methodology
      1.3. Key Assumptions

      1.4. Acronyms

2. Scope of Study

      2.1. Market Definition
      .2. Objective of the Research

      2.3. Regions covered in the study

3. Executive summary

4. Branded Generics in Emerging Countries Market Dynamics

      4.1. Drivers
            4.1.1. Economic Drivers
            4.1.2. Demand Side Drivers
            4.1.3. Supply Side Drivers
      4.2. Restraints
      4.3. Opportunities/Unmet Needs of the Market

      4.4. Trends

5. Unique Features of the Report

      5.1. Competition analysis
      5.2. Regulatory landscape
      5.3. PESTLE analysis

      5.4. Porter’s analysis

6. Branded Generics in Emerging Countries Market Analysis, By Diseases Indication, 2013 – 2017 and Forecast, 2018 – 2024

      6.1. Cardiovascular Diseases
            6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
            6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      6.2. Diabetes
            6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
            6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      6.3. Cancer
            6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
            6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      6.4. Neurological Disorders
            6.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
            6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      6.5. Gastrointestinal Diseases
            6.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
            6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      6.6. Dermatology Diseases
            6.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
            6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      6.7. Others
            6.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

            6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

7. Branded Generics in Emerging Countries Market Analysis, By Route of Administration, 2013 – 2017 and Forecast, 2018 – 2024

      7.1. Oral
            7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024(Revenue, USD Mn)
            7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      7.2. Parenteral
            7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024(Revenue, USD Mn)
            7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      7.3. Topical
            7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024(Revenue, USD Mn)
            7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      7.4. Others
            7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024(Revenue, USD Mn)

            7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

8. Branded Generics in Emerging Countries Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024

      8.1. Hospital Pharmacies
            8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024(Revenue, USD Mn)
            8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      8.2. Retail Pharmacies
            8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024(Revenue, USD Mn)
            8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      8.3. Drug Stores
            8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024(Revenue, USD Mn)
            8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      8.4. Online Pharmacies
            8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024(Revenue, USD Mn)

            8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9. Branded Generics in Emerging Countries Market Analysis, By Region, 2013 – 2017 and Forecast, 2018 – 2024

      9.1. Europe Branded Generics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
            9.1.1. Diseases Indication Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.1.1.1. Cardiovascular Diseases
                  9.1.1.2. Diabetes
                  9.1.1.3. Cancer
                  9.1.1.4. Neurological Disorders
                  9.1.1.5. Gastrointestinal Diseases
                  9.1.1.6. Dermatology Diseases
                  9.1.1.7. Others
            9.1.2. Route of Administration Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.1.2.1. Oral
                  9.1.2.2. Parenteral
                  9.1.2.3. Topical
                  9.1.2.4. Others
            9.1.3. Distribution Channel Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.1.3.1. Hospital Pharmacies
                  9.1.3.2. Retail Pharmacies
                  9.1.3.3. Drug Stores
                  9.1.3.4. Online Pharmacies
            9.1.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.1.4.1. Russia
                  9.1.4.2. Romania
                  9.1.4.3. Rest of Europe
      9.2. Asia-Pacific Branded Generics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
            9.2.1. Diseases Indication Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.2.1.1. Cardiovascular Diseases
                  9.2.1.2. Diabetes
                  9.2.1.3. Cancer
                  9.2.1.4. Neurological Disorders
                  9.2.1.5. Gastrointestinal Diseases
                  9.2.1.6. Dermatology Diseases
                  9.2.1.7. Others
            9.2.2. Route of Administration Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.2.2.1. Oral
                  9.2.2.2. Parenteral
                  9.2.2.3. Topical
                  9.2.2.4. Others
            9.2.3. Distribution Channel Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.2.3.1. Hospital Pharmacies
                  9.2.3.2. Retail Pharmacies
                  9.2.3.3. Drug Stores
                  9.2.3.4. Online Pharmacies
            9.2.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.2.4.1. China
                  9.2.4.2. India
                  9.2.4.3. ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
                  9.2.4.4. Rest of Asia- Pacific
      9.3. Latin America Branded Generics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
            9.3.1. Diseases Indication Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.3.1.1. Cardiovascular Diseases
                  9.3.1.2. Diabetes
                  9.3.1.3. Cancer
                  9.3.1.4. Neurological Disorders
                  9.3.1.5. Gastrointestinal Diseases
                  9.3.1.6. Dermatology Diseases
<

            /div>

      9.3.1.7. Others
            9.3.2. Route of Administration Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.3.2.1. Oral
                  9.3.2.2. Parenteral
                  9.3.2.3. Topical
                  9.3.2.4. Others
            9.3.3. Distribution Channel Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.3.3.1. Hospital Pharmacies
                  9.3.3.2. Retail Pharmacies
                  9.3.3.3. Drug Stores
                  9.3.3.4. Online Pharmacies
            9.3.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.3.4.1. Brazil
                  9.3.4.2. Poland
                  9.3.4.3. Argentina
                  9.3.4.4. Mexico
                  9.3.4.5. Venezuela
                  9.3.4.6. Rest of Latin America
      9.4. Rest of the World (RoW) Branded Generics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
            9.4.1. Diseases Indication Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.4.1.1. Cardiovascular Diseases
                  9.4.1.2. Diabetes
                  9.4.1.3. Cancer
                  9.4.1.4. Neurological Disorders
                  9.4.1.5. Gastrointestinal Diseases
                  9.4.1.6. Dermatology Diseases
                  9.4.1.7. Others
            9.4.2. Route of Administration Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.4.2.1. Oral
                  9.4.2.2. Parenteral
                  9.4.2.3. Topical
                  9.4.2.4. Others
            9.4.3. Distribution Channel Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.4.3.1. Hospital Pharmacies
                  9.4.3.2. Retail Pharmacies
                  9.4.3.3. Drug Stores
                  9.4.3.4. Online Pharmacies
            9.4.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.4.4.1. Turkey
                  9.4.4.2. Saudi Arabia
                  9.4.4.3. South Africa

                  9.4.4.4. Egypt

10. Competition Landscape

      10.1. Strategic Dashboard of Top Market Players
      10.2. Company Profiles (Introduction, Financial Analysis, Products & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
            10.2.1. Abbott Laboratories (U.S.)
            10.2.2. Apotex Inc. (Canada)
            10.2.3. AstraZeneca (U.K)
            10.2.4. CSPC Pharmaceutical Group Limited. (China)
            10.2.5. Dr. Reddy’s Laboratories Ltd. (India)
            10.2.6. GlaxoSmithKline plc (U.K)
            10.2.7. Mylan N.V. (U.S.)
            10.2.8. Nichi-Iko Pharmaceutical Co., Ltd ( Japan)
            10.2.9. Novartis AG (Switzerland)
            10.2.10. Pfizer Inc. (U.S)
            10.2.11. Sanofi (France)
            10.2.12. Sun Pharmaceutical Industries Ltd. (India)
            10.2.13. Teva Pharmaceutical Industries Ltd (Israel)

            10.2.14. Valeant Pharmaceuticals International, Inc. (Canada)


Report

Company Profile

  • Abbott Laboratories (U.S.)
  • Apotex Inc. (Canada)
  • AstraZeneca (U.K)
  • Reddy’s Laboratories Ltd. (India)
  • GlaxoSmithKline plc (U.K)
  • Mylan N.V. (U.S.)
  • Pfizer Inc. (U.S)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Valeant Pharmaceuticals International, Inc. (Canada)

Description

The global branded generics market size valued US$ 224.0 billion in 2017 and expected to reach US$ 350.0 billion by 2023, poised to grow at CAGR 7.7 % during forecast period 2021-2023. Branded generics are the most recent version of an off-patent drug that is promoted by either a patented drug manufacturer or generic drug companies that build brand equity for their generic drug versions. The pharmaceutical sector is characterised by a number of internal and external dynamics linked to licencing, production, and marketing. The notion of patenting is extremely important in the pharmaceutical industry. The branded generics market expected to register around double-digit growth rate in emerging economies owing to the widespread prevalence of lifestyle and chronic diseases like diabetes and cardiovascular diseases. The growing lifestyle changes along with rising disposable income in middle classes are factors expected to prompt the market growth in near future. According to International Diabetes Federation (IDF) atlas, 2015 emerging nations like India and China, Brazil and Russia fall under top ten countries for diabetic population. This report studies branded generics market dynamics in emerging markets and developed markets elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes new product introductions, recent drug patent expiration data, regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the competition. Moreover, PBI analyzed branded generics market to better equip clients with possible investment opportunities across the emerging markets (Regional Investment Hot-Spots) and unmet needs (Product/Disease Opportunities).

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX